GenVec/Novartis

GenVec was founded in 1992, with the mission to develop gene-based medicine. GenVec has partnered with Novartis, with the mission of developing a product candidate that can restore hearing and vestibular function, code-named CGF166. It is the first gene-based therapeutic agent and the first ever regenerative drug to be used in a man, with the aim to restore hearing and vestibular function. GenVec is currently recruiting patients with bilateral severe to profound hearing loss for a phase 2 clinical trial.

Clinical Trials — Recruiting

Safety, Tolerability and Efficacy for CGF166 in Patients With Bilateral Severe-to-profound Hearing Loss

Condition: Bilateral Severe to Profound Hearing Loss
Intervention: Drug: CGF166
Phase: Phase 1; Phase 2

RECENT NEWS ON GENVEC/NOVARTIS

Nothing Found

Sorry, no posts matched your criteria

COMPANY OVERVIEW

Genvec

Locations: United States
Year Founded: 1992
CEO: Douglas J. Swirsky (CPA, CFA)